DoH Policies screened during the period: 1 April 2023 - 30 June 2023
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- NICE Clinical Guideline NG231 - Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (updates and replaces CG106) (PDF 511KB)
- NICE Technology Appraisal TA875 - Semaglutide for managing overweight and obesity (PDF 566KB)
- NICE Technology Appraisal TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (PDF 511KB)
- NICE Technology Appraisal TA877 - Finerenone for treating chronic kidney disease in type 2 diabetes (PDF 557KB)
- NICE Technology Appraisal TA880 – Tezepelumab for treating severe asthma (PDF 514KB)
- NICE Public Health Guideline NG183 - Behaviour change: digital and mobile health interventions (PDF 517KB)
- NICE Technology Appraisal TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (PDF 639KB)
- NICE Technology Appraisal TA881 – Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (PDF 510KB)
- NICE Technology Appraisal TA882 – Voclosporin with mycophenolate mofetil for treating lupus nephritis (PDF 514KB)
- NICE Public Health Guideline NG223 – Social, emotional and mental wellbeing in primary and secondary education. (PDF 518KB)
- NICE TA885 – regarding Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (PDF 512KB)
- NICE Technology Appraisal TA886 - Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (PDF 513KB)
- NICE Technology Appraisal TA887 - Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer rapid review of TA831 (PDF 513KB)
- NICE Technology Appraisal TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease (PDF 511KB)
- NICE Technology Appraisal TA890 - Difelikefalin for treating pruritus in people having haemodialysis (PDF 512KB)hocytic leukaemia (PDF 512KB)
- NICE Technology Appraisal TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (PDF 512KB)
- NICE Technology Appraisal TA892 - Mosunetuzumab for treating relapsed or refractory follicular lymphoma (PDF 513KB)
- NICE Technology Appraisal TA893 - Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (PDF 626KB)
- NICE Technology Appraisal TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (PDF 510KB)
- NICE Technology Appraisal TA896 - Bulevirtide for treating chronic hepatitis D (PDF 511KB)
- NICE Technology Appraisal TA897 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (review of TA573 (PDF 511KB)
- NICE Technology Appraisal TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (PDF 513KB)
- SPPG The Enhancing Clinical Care Framework for Adults living in care homes (PDF 561KB)
- SPPG Northern Ireland Local Enhanced Service: Quality Improvement Service (PDF 956KB)